

AMENDMENTS TO THE SPECIFICATION:

Pursuant to the revised 37 § CFR 1.121, please amend the specification as follows:

Please replace the paragraph beginning at page 32, line 29 with the following amended paragraph:

The present invention identifies culture conditions and additives that induce differentiation of unique subtypes or subsets of DC that are phenotypically and functionally different from conventional DC produced in RPMI. In one embodiment, the mDC2 of the invention are produced by culturing a population of mononuclear cells or monocytes with IL-4, GM-CSF, and a culture medium comprising Iscove's Modified Dulbecco's Medium (IMDM) (as described in the Gibco BRL Life Technologies Products & Reference Guide 2000-2001 and its website, <http://www.lifetech.com>, Gibco BRL Life Technologies Rockville, MD (see, e.g., the IMDM media described in Gibco BRL Life Technologies Products & Reference Guide 2000-2001, p. 1-52, Catalog Nos. 12200, 12440, 31980, and preferably 21056), which is incorporated herein by reference in its entirety for all purposes. Other growth factors and additives, such as insulin, transferrin, and lipids or fatty acids (e.g., C₁₆ – C₁₈ fatty acids, and isomers, derivatives, and analogs thereof) can also be used to supplement IMDM to generate mDC2 possessing the phenotypic and/or functional characteristics described herein. For examples of C₁₆ – C₁₈ fatty acids, and isomers, derivatives, and analogs thereof, see Voet, Voet, and Pratt, **FUNDAMENTALS OF BIOCHEMISTRY** (John Wiley & Sons, Inc. 1999), which is incorporated by reference herein in its entirety for all purposes.